MetaCap

Dyne Therapeutics (DYN) vs Xeris Biopharma (XERS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xeris Biopharma (XERS) has outperformed Dyne Therapeutics (DYN) over the past year, gaining 148.5% versus a loss of 26.8%. Over five years, XERS leads with a +682.0% price change compared with +5.4% for DYN. Xeris Biopharma is the larger company by market cap ($3.10 billion vs $2.90 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DYN-26.82%XERS+148.46%
+158%+58%-42%
Nov 21, 20251 yearNov 20, 2026
DYN-1.84%XERS+647.58%
+684%+288%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DYN versus XERS key metrics
MetricDYNXERS
Share price$15.50$16.97
Market cap$2.90B$3.10B
1-day change-3.31%+2.11%
YTD return-20.76%+116.18%
1-year return-26.82%+148.46%
5-year return+5.37%+682.03%
Forward P/E—63.64
EPS (TTM)$-3.62$-0.03
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$291.85M
Revenue growth (YoY)—+43.72%
Net income (latest FY)$-446.21M$554.00K
Gross margin—85.41%
Operating margin—8.53%
Net margin—0.19%
52-week high$27.31$17.28
52-week low$14.00$5.25
Distance from 52-week high-43.23%-1.79%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+121.48%+1.89%
Average volume2.94M2.86M
Shares outstanding187.39M182.70M
Employees322435
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XERS has outperformed DYN by 175.3 percentage points over the past year.

About Dyne Therapeutics

DYN stock →

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

Health Care · Biotechnology: Pharmaceutical Preparations · 322 employees

About Xeris Biopharma

XERS stock →

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 435 employees

DYN vs XERS FAQ

Which is bigger, Dyne Therapeutics or Xeris Biopharma?

Xeris Biopharma (XERS) is larger, with a market capitalization of $3.10B compared with $2.90B for Dyne Therapeutics (DYN).

Which stock has performed better over the past year, DYN or XERS?

XERS returned +148.46% over the past 12 months, compared with -26.82% for DYN (price return, excluding dividends). Past performance does not predict future results.

Are Dyne Therapeutics and Xeris Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons